Division of Fujifilm Holdings Corp.
Latest From Fujifilm Corp.
Diversified Japanese giant gains global rights to Cynata’s novel therapy for GvHD as part of continued push into cell and regenerative medicine, amid ongoing discussions between Sumitomo Dainippon and the Australian bioventure over a potential wider acquisition.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
Autumn has brought a flurry of personnel changes with Kyowa FujiFilm getting a new president and AZ a new executive vice president for the international region. Fosun and the medtech firm, Median Technologies, have also seen personnel movement.
- Contract Research, Toxicology Testing-CRO
- Diagnostic Imaging Equipment & Supplies
- Generic Drugs
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Fujifilm Holdings Corp.
- Senior Management
- Shigetaka Komori, Pres. & CEO
- Contact Info
Midtown West, 7-3, Akasaka 9-chome
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.